股息配發率   玩股撇步(動畫小學堂)

  • 現金殖利率: 5.15%、總殖利率: 5.15%、5年平均現金配發率: 89.01%
  • 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
  • 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
EPS YoY現金股利 YoY股票股利 YoY現金配發率 YoY股票配發率 YoY全部配發率 YoY
2025 (5)3.6223.132.6123.110.00072.10-0.010.00072.10-0.01
2024 (4)2.9482.612.1265.620.00072.11-9.30.00072.11-9.3
2023 (3)1.610.01.28-20.00.00079.50-20.00.00079.50-20.0
每股盈餘-近8季
EPS QoQ YoY本業EPS QoQ YoY累計EPS QoQ YoY
26Q1 (8)1.0162.927.850.9783.0231.081.01-72.1827.85
25Q4 (7)0.62-59.48148.00.53-60.4526.193.6320.623.05
25Q3 (6)1.53125.021.431.34112.718.583.01104.7611.48
25Q2 (5)0.68-13.9283.780.63-14.8696.881.4786.082.8
25Q1 (4)0.79216.00.00.7476.190.00.79-73.220.0
24Q4 (3)0.25-80.160.00.42-62.830.02.959.260.0
24Q3 (2)1.26240.540.01.13253.120.02.7088.810.0
24Q2 (1)0.370.00.00.320.00.01.430.00.0
年/月營收月增率(%)去年同期年增率(%)累計營收累計營收年增率(%)近三月累計營收存貨銷售比自結稅前EPS自結稅前累計EPS備註(年增率變動50%需說明原因)
2026/51.2616.3434.455.211.653.43N/A-
2026/41.08-0.427.373.945.92.87N/A-
2026/31.0955.515.562.86-0.452.860.48-
2026/20.7-34.63-35.91.77-8.272.830.49-
2026/11.071.2727.721.0727.723.310.42-
2025/121.06-10.434.2313.4420.493.650.43-
2025/111.18-16.6728.2812.3922.115.020.31-
2025/101.42-41.6444.9511.2121.54.80.33-
2025/92.43154.568.979.7918.724.230.45-
2025/80.9512.87.417.3622.322.70.71-
2025/70.85-6.569.716.4124.912.690.71-
2025/60.9-3.5230.025.5627.592.690.61-
2025/50.9410.213.324.6627.132.730.6-
2025/40.85-9.6313.03.7234.962.880.57-
2025/30.94-13.7581.022.8743.22.870.64本⽉營收較去年同期增加,係市場需求增加及⼦公司合併營收增加所致。
2025/21.0930.24217.561.9329.962.940.62本月營收較去年同期增加,主係市場需求增加及子公司合併營收增加所致。
2025/10.84-17.34-26.550.84-26.552.770.66-
2024/121.0110.2241.1611.1637.582.910.6-
2024/110.92-5.8444.4510.1437.234.120.43-
2024/100.98-56.057.569.2236.554.090.43-
2024/92.22150.4739.038.2440.993.880.45-
2024/80.8915.2245.526.0241.732.350.74-
2024/70.7710.7258.815.1341.12.370.73於民國一一三年四月九日取得高峰藥品材料股份有限公司及高峰生技股份有限公司各51%已發行流通在外普通股, 係以合併營業收入申報.
2024/60.7-23.333.664.3638.372.360.75-
2024/50.9120.5465.03.6747.772.180.81於民國113年4月9日取得高峰藥品材料股份有限公司及高峰生技股份有限公司各51%已發行流通在外普通股,係以合併營業收入申報.
2024/40.7544.7456.252.7642.851.621.09於民國一一三年四月九日取得高峰藥品材料股份有限公司及高峰生技股份有限公司各51%已發行流通在外普通股, 係以合併營業收入申報.
2024/30.5251.29-0.822.038.42.0N/A-
2024/20.34-69.87-23.091.4860.662.21N/A因認列藥證移轉勞務收入與市場需求增加,故本年累計營收較去年同期增加。
2024/11.1458.21139.131.14139.132.3N/A因適逢農曆春節連續假期備貨與藥證移轉勞務收入所致,故較去年同期增加。
2023/120.7265.8458.138.1174.681.57N/A依據財務會計準則之相關規定,本公司併購創益公司,係屬集團內之組織重組,視為自始合併不受設立日之限制,故營收為合併淨額。
2023/110.434.2711.554.538.191.28N/A-
2023/100.42-1.7911.044.17.841.25N/A-
2023/90.424.013.483.687.491.24N/A-
2023/80.411.0311.393.258.041.26N/A-
2023/70.4-9.7417.252.857.571.27N/A-
2023/60.455.9524.262.446.121.27N/A-
2023/50.426.4915.81.992.751.23N/A-
2023/40.4-4.426.931.57-0.261.16N/A-
2023/30.4219.85-1.941.17-2.471.17N/A-
2023/20.35-16.1423.170.76-2.771.22N/A-
2023/10.41-9.43-17.360.41-17.361.26N/A-
2022/120.4616.9922.924.6412.31.22N/A-
2022/110.393.87.694.1911.261.18N/A-
2022/100.38-8.489.533.811.641.15N/A-
2022/90.4111.9616.243.4211.871.12N/A-
2022/80.376.357.883.0111.31.07N/A-
2022/70.34-4.3416.532.6511.791.07N/A-
2022/60.36-1.257.232.311.121.1N/A-
2022/50.36-1.66-0.361.9411.871.16N/A-
2022/40.37-12.365.771.5815.141.08N/A-
2022/30.4250.568.841.218.381.2N/A-
2022/20.28-43.747.60.7824.281.15N/A-
2022/10.534.7236.150.536.151.23N/A-
2021/120.372.5-23.224.13-7.671.08N/A-
2021/110.365.572.733.76-5.791.06N/A-
2021/100.34-2.87-16.983.4-6.621.04N/A-
2021/90.353.917.213.06-5.290.99N/A-
2021/80.3414.88-2.052.71-7.60.97N/A-
2021/70.3-11.98-16.572.37-8.350.0N/A-
2021/60.34-8.2510.612.07-7.040.0N/A-

免責聲明

本網站所有資料僅供參考,如使用者依本資料交易發生交易損失需自行負責,本網站對資料內容錯誤﹑更新延誤不負任何責任。